Eledon Pharmaceuticals Inc's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Eledon Pharmaceuticals Inc's ROI in the second quarter of 2026?
Eledon Pharmaceuticals Inc recorded a cumulative net loss of $-95 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -93.23%.

Within the Healthcare sector 307 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 3345 to 3890.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Investment Change TTM	25.35 %	31.21 %	58.53 %	116.07 %	122.42 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	73	131	149	56	73
Return On Investment (TTM)	-93.23 %	-73.69 %	-45.75 %	-65.55 %	19.02 %
ELDN's Overall Ranking	# 3890	# 3345	# 2910	#	#
Seq. Investment Change TTM	-0.11 %	9.25 %	11.42 %	3.08 %	4.57 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-95	-75	-43	-55	15

ELDN Company Profile >> Back to ELDN Roi Comparisons >> See Annual ELDN Return On Investment

Return On Investment ELDN's Ranking
Within:	No.
Industry	# 127
Sector	# 308
Overall	# 3890

Return On Investment Statistics
High	Average	Low
12.57 %	-67.79 %	-178.38 %
(Jun 30 2025)		(Jun 30 2024)

News about Eledon Pharmaceuticals Inc Return on Investment ROI

Eledon Pharmaceuticals Advances Immunosuppressive Therapies with Successful Trial Enrollment and Major Stock Offering

October 29, 2024

In a significant development within the biotechnology sector, Eledon Pharmaceuticals has made notable strides in its mission to enhance organ transplant outcomes. The company recently announced the successful completion of patient enrollment for its Phase 2 BESTOW clinical trial, aimed at evaluating the efficacy of its lead investigational drug, Tegoprubart, in preventing organ rejection among kidney transplant recipients. This milestone is underscored by the company’s concurrent capital-raising efforts, signaling robust confidence in its innovative approach to transplant medicine.A Closer Look at the BESTOW TrialThe BESTOW trial is a pivotal study designed to address a pressing issue in transplant medicine: the risk of organ rejection. After undergoing kidney transplantation, patients face various challenges, including the formidable threat of their immune systems rejecting the new organ. Tegoprubart represents a new class of agents that aim to modulate the immune response more effectively than traditional immunosuppressive therapies. With completed enrollment, Eledon Pharmaceuticals is now positioned to derive crucial data that could transform treatment paradigms for kidney transplant patients.

Financial Statements
Eledon Pharmaceuticals Inc's II. Quarter Investments	$ 73 Millions	ELDN's Balance sheet
Eledon Pharmaceuticals Inc's II. Quarter Income	$ -30 Millions	Quarterly ELDN's Income Statement
ELDN's Income by Division		See ELDN's Income by Division

ELDN Annual Return On Investment	(Dec 31 2025) 2025	(Dec 31 2024) 2024	(Dec 31 2023) 2023	(Dec 31 2022) 2022	(Dec 31 2021) 2021
Total Investments in Millions	149	166	85	86	166
Y / Y Investment Growth	-10.44 %	94.7 %	-1.33 %	-48.05 %	-14.67 %
Net Income in Millions	-46	-36	-117	-88	-35
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-30.72 %	-21.82 %	-136.83 %	-101.91 %	-20.77 %

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ELDN's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ELDN's Competitors
Subscribers only: Roi for Eledon Pharmaceuticals Inc's Suppliers
Subscribers only: Return On Investment for ELDN's Customers

Other Ratios
ELDN's Roa	ELDN's Inventory Turnover Ratio	ELDN's Growth Rates	ELDN's Dividend Statistics
	ELDN's Profitability Ratios	ELDN's Asset Turnover Ratio	ELDN's Dividend Growth
ELDN's Roe	ELDN's Valuation Ratios	ELDN's Financial Strength Ratios	ELDN's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-03T15:58:10+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.